Abeona Therapeutics (ABEO) Cash & Equivalents (2010 - 2026)

Abeona Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $61.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 285.13% year-over-year to $61.4 million; the TTM figure through Mar 2026 stood at $61.4 million (up 285.13% YoY), while the FY2025 annual figure was $78.4 million, up 231.03% from the prior year.
• Cash & Equivalents was $61.4 million for Q1 2026 at Abeona Therapeutics, down from $78.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $163.9 million in Q2 2025 to a low of $5.0 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $34.4 million across 5 years, with a median of $16.1 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents tumbled 87.19% in 2022, then jumped 429.7% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $14.6 million in 2022, then climbed by 1.76% to $14.8 million in 2023, then soared by 59.98% to $23.7 million in 2024, then surged by 231.03% to $78.4 million in 2025, then fell by 21.75% to $61.4 million in 2026.
• The last three Cash & Equivalents figures came in at $61.4 million (Q1 2026), $78.4 million (Q4 2025), and $83.2 million (Q3 2025), per Business Quant data.